A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.

Timo Vesikari; Nicholas Brodszki; Pierre van Damme; Javier Diez-Domingo; Giancarlo Icardi; Lone Kjeld Petersen; Clément Tran; Stéphane Thomas; Alain Luxembourg; Martine Baudin

doi:10.1097/INF.0000000000000773

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.

Timo Vesikari, Nicholas Brodszki, Pierre van Damme, Javier Diez-Domingo, Giancarlo Icardi, Lone Kjeld Petersen, Clément Tran, Stéphane Thomas, Alain Luxembourg, Martine Baudin

Paediatrics (Lund)

Research output: Contribution to journal › Article › peer-review

Abstract

A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.

Original language	English
Pages (from-to)	992-998
Journal	Pediatric Infectious Disease Journal
Volume	34
Issue number	9
DOIs	https://doi.org/10.1097/INF.0000000000000773
Publication status	Published - 2015

Subject classification (UKÄ)

Pediatrics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/INF.0000000000000773

http://www.ncbi.nlm.nih.gov/pubmed/26090572?dopt=Abstract

Cite this

Vesikari, T., Brodszki, N., van Damme, P., Diez-Domingo, J., Icardi, G., Kjeld Petersen, L., Tran, C., Thomas, S., Luxembourg, A., & Baudin, M. (2015). A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls. Pediatric Infectious Disease Journal, 34(9), 992-998. https://doi.org/10.1097/INF.0000000000000773

@article{4385140ef7eb40d8841b4e8bc14cdafb,

title = "A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil{\textregistered}in 9-15-Year-Old Girls.",

abstract = "A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.",

author = "Timo Vesikari and Nicholas Brodszki and {van Damme}, Pierre and Javier Diez-Domingo and Giancarlo Icardi and {Kjeld Petersen}, Lone and Cl{\'e}ment Tran and St{\'e}phane Thomas and Alain Luxembourg and Martine Baudin",

year = "2015",

doi = "10.1097/INF.0000000000000773",

language = "English",

volume = "34",

pages = "992--998",

journal = "Pediatric Infectious Disease Journal",

issn = "1532-0987",

publisher = "Lippincott Williams & Wilkins",

number = "9",

}

Vesikari, T, Brodszki, N, van Damme, P, Diez-Domingo, J, Icardi, G, Kjeld Petersen, L, Tran, C, Thomas, S, Luxembourg, A & Baudin, M 2015, 'A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.', Pediatric Infectious Disease Journal, vol. 34, no. 9, pp. 992-998. https://doi.org/10.1097/INF.0000000000000773

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls. / Vesikari, Timo; Brodszki, Nicholas; van Damme, Pierre et al.
In: Pediatric Infectious Disease Journal, Vol. 34, No. 9, 2015, p. 992-998.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.

AU - Vesikari, Timo

AU - Brodszki, Nicholas

AU - van Damme, Pierre

AU - Diez-Domingo, Javier

AU - Icardi, Giancarlo

AU - Kjeld Petersen, Lone

AU - Tran, Clément

AU - Thomas, Stéphane

AU - Luxembourg, Alain

AU - Baudin, Martine

PY - 2015

Y1 - 2015

N2 - A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.

AB - A 9-valent human papillomavirus (9vHPV) vaccine has been developedto prevent infections and diseases related to HPV 6/11/16/18 (as per the licensed quadrivalent HPV [qHPV] vaccine), as well as 5additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine vs. the qHPV vaccine in 9-15-year-old girls.

U2 - 10.1097/INF.0000000000000773

DO - 10.1097/INF.0000000000000773

M3 - Article

C2 - 26090572

SN - 1532-0987

VL - 34

SP - 992

EP - 998

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 9

ER -

A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this